Differentially expressed genes in patients' peripheral blood mononuclear cells during 24 hours of vorinostat treatment. a

aLog2-fold change higher than 1.0; P-value less than 0.01.bGenes in bold: chosen for validation of expression in the study patients' peripheral blood mononuclear cells (PBMC) samples and human colorectal carcinoma xenograft models.cT0 represents baseline PBMC samples; T2 and T24 represent PBMC samples collected two and 24 hours, respectively, after the patients had received the daily dose of vorinostat.